Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct 6;10(10):CD012432.
doi: 10.1002/14651858.CD012432.pub2.

Interventions for managing medication-related osteonecrosis of the jaw

Natalie H Beth-Tasdogan  1 , Benjamin Mayer, Heba Hussein, Oliver Zolk
Affiliations

Interventions for managing medication-related osteonecrosis of the jaw

Natalie H Beth-Tasdogan et al. Cochrane Database Syst Rev. .

Update in

Abstract

Background: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, the occurrence of this adverse drug reaction may be rare (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent-targeted cancer treatment) or common (e.g. following intravenous bisphosphonate for cancer treatment). MRONJ is associated with significant morbidity, adversely affects quality of life (QoL), and is challenging to treat.

Objectives: To assess the effects of interventions versus no treatment, placebo, or an active control for the prophylaxis of MRONJ in people exposed to antiresorptive or antiangiogenic drugs.To assess the effects of non-surgical or surgical interventions (either singly or in combination) versus no treatment, placebo, or an active control for the treatment of people with manifest MRONJ.

Search methods: Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 23 November 2016), the Cochrane Central Register of Controlled Trials (CENTRAL) (the Cochrane Library, 2016, Issue 10), MEDLINE Ovid (1946 to 23 November 2016), and Embase Ovid (23 May 2016 to 23 November 2016). The US National Institutes of Health Trials Registry (ClinicalTrials.gov) and the World Health Organization International Clinical Trials Registry Platform were searched for ongoing trials. No restrictions were placed on language or publication status when searching the electronic databases; however, the search of Embase was restricted to the last six months due to the Cochrane Embase Project to identify all clinical trials and add them to CENTRAL.

Selection criteria: We included randomised controlled trials (RCTs) comparing one modality of intervention with another for the prevention or treatment of MRONJ. For 'prophylaxis of MRONJ', the primary outcome of interest was the incidence of MRONJ; secondary outcomes were QoL, time-to-event, and rate of complications and side effects of the intervention. For 'treatment of established MRONJ', the primary outcome of interest was healing of MRONJ; secondary outcomes were QoL, recurrence, and rate of complications and side effects of the intervention.

Data collection and analysis: Two review authors independently screened the search results, extracted the data, and assessed the risk of bias in the included studies. For dichotomous outcomes, we reported the risk ratio (RR) (or rate ratio) and 95% confidence intervals (CI).

Main results: We included five RCTs (1218 participants) in the review. Three trials focused on the prophylaxis of MRONJ. Two trials investigated options for the treatment of established MRONJ. The RCTs included only participants treated with bisphosphonates and, thus, did not cover the entire spectrum of medications associated with MRONJ. Prophylaxis of MRONJOne trial compared standard care with regular dental examinations in three-month intervals and preventive treatments (including antibiotics before dental extractions and the use of techniques for wound closure that avoid exposure and contamination of bone) in men with metastatic prostate cancer treated with zoledronic acid. The intervention seemed to lower the risk of MRONJ: RR 0.10; 95% CI 0.02 to 0.39 (253 participants; low-quality evidence). Secondary outcomes were not evaluated.As dentoalveolar surgery is considered a common predisposing event for developing MRONJ, one trial investigated the effect of plasma rich in growth factors (PRGF) for preventing MRONJ in people with cancer undergoing dental extractions. There was insufficient evidence to support or refute a benefit of PRGF on MRONJ incidence when compared with standard treatment (RR 0.08, 95% CI 0.00 to 1.51; 176 participants; very low-quality evidence). Secondary outcomes were not reported. In another trial comparing wound closure by primary intention with wound closure by secondary intention after dental extractions in people treated with oral bisphosphonates (700 participants), no cases of intraoperative complications or postoperative MRONJ were observed. QoL was not investigated. Treatment of MRONJOne trial analysed hyperbaric oxygen (HBO) treatment used in addition to standard care (antiseptic rinses, antibiotics, and surgery) compared with standard care alone. HBO in addition to standard care did not significantly improve healing from MRONJ compared with standard care alone (at last follow-up: RR 1.56; 95% CI 0.77 to 3.18; 46 participants included in the analysis; very low-quality evidence). QoL data were presented qualitatively as intragroup comparisons; hence, an effect estimate of treatment on QoL was not possible. Other secondary outcomes were not reported.The other RCT found no significant difference between autofluorescence- and tetracycline fluorescence-guided sequestrectomy for the surgical treatment of MRONJ at any timepoint (at one-year follow-up: RR 1.05; 95% CI 0.86 to 1.30; 34 participants included in the analysis; very low-quality evidence). Secondary outcomes were not reported.

Authors' conclusions: Prophylaxis of MRONJOne open-label RCT provided some evidence that dental examinations in three-month intervals and preventive treatments may be more effective than standard care for reducing the incidence of MRONJ in individuals taking intravenous bisphosphonates for advanced cancer. We assessed the certainty of the evidence to be low.There is insufficient evidence to either claim or refute a benefit of either of the interventions tested for prophylaxis of MRONJ (i.e. PRGF inserted into the postextraction alveolus during dental extractions, and wound closure by primary or secondary intention after dental extractions). Treatment of MRONJAvailable evidence is insufficient to either claim or refute a benefit for hyperbaric oxygen therapy as an adjunct to conventional therapy. There is also insufficient evidence to draw conclusions about autofluorescence-guided versus tetracycline fluorescence-guided bone surgery.

PubMed Disclaimer

Conflict of interest statement

There are no financial conflicts of interest and the review authors declare that they do not have any associations with any parties who may have vested interests in the results of this review.

  1. Natalie H Beth‐Tasdogan: no interests to declare

  2. Benjamin Mayer: no interests to declare

  3. Heba Hussein: no interests to declare

  4. Oliver Zolk: no interests to declare

Figures

1
1
Study flow diagram. Results of the search strategy for inclusion of studies in this review
2
2
'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

References to studies included in this review

Freiberger 2012 {published data only}
    1. Freiberger JJ, Padilla‐Burgos R, McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of hyperbaric oxygen in the management of bisphosphonate‐related osteonecrosis of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct to surgery and antibiotics. Journal of Oral and Maxillofacial Surgery 2012;70(7):1573‐83. [DOI: 10.1016/j.joms.2012.04.001; PUBMED: 22698292] - DOI - PubMed
    1. NCT00462098. Randomized controlled trial of hyperbaric oxygen in patients who have taken bisphosphonates. clinicaltrials.gov/show/NCT00462098 (first received 10 April 2007).
Mozzati 2012 {published data only}
    1. Mozzati M, Arata V, Gallesio G. Tooth extraction in patients on zoledronic acid therapy. Oral Oncology 2012;48(9):817‐21. [DOI: 10.1016/j.oraloncology.2012.03.009; PUBMED: 22483860] - DOI - PubMed
    1. Mozzati M, Arata V, Gallesio G, Carossa S. A dental extraction protocol with plasma rich in growth factors (PRGF) in patients on intravenous bisphosphonate therapy: a case‐control study. Joint, Bone, Spine 2011;786(6):648‐9. [DOI: 10.1016/j.jbspin.2011.04.017; PUBMED: 21703903] - DOI - PubMed
Mozzati 2013 {published data only}
    1. Mozzati M, Arata V, Gallesio G. Tooth extraction in osteoporotic patients taking oral bisphosphonates. Osteoporosis International 2013;24(5):1707‐1. [DOI: 10.1007/s00198-012-2239-8; PUBMED: 23288026] - DOI - PubMed
    1. Mozzati M, Arata V, Gallesio G, Carossa S. Tooth extraction and oral bisphosphonates: comparison of different surgical protocol. Joint, Bone, Spine 2011;78(6):647‐8. [DOI: 10.1016/j.jbspin.2011.04.018; PUBMED: 21703902] - DOI - PubMed
Mücke 2016 {published data only}
    1. Mücke T, Deppe H, Hein J, Wolff KD, Mitchell DA, Kesting MR, et al. Prevention of bisphosphonate‐related osteonecrosis of the jaws in patients with prostate cancer treated with zoledronic acid ‐ a prospective study over 6 years. Journal of Cranio‐maxillo‐facial Surgery 2016;44(10):1689‐93. [DOI: 10.1016/j.jcms.2016.07.026; 27555374] - DOI - PubMed
Ristow 2016 {published data only}
    1. Ristow O, Otto S, Geiß C, Kehl V, Berger M, Troeltzsch M, et al. Comparison of auto‐fluorescence and tetracycline fluorescence for guided bone surgery of medication‐related osteonecrosis of the jaw: a randomized controlled feasibility study. International Journal of Oral and Maxillofacial Surgery 2017;46(2):157‐66. [DOI: 10.1016/j.ijom.2016.10.008; PUBMED: 27856150] - DOI - PubMed

References to studies excluded from this review

Asaka 2016 {published data only}
    1. Asaka T, Ohga N, Yamazaki Y, Sato J, Satoh C, Kitagawa Y. Platelet‐rich fibrin may reduce the risk of delayed recovery in tooth‐extracted patients undergoing oral bisphosphonate therapy: a trial study. Clinical Oral Investigations 2016 Nov 11 [Epub ahead of print]. [DOI: 10.1007/s00784-016-2004-z] - DOI - PubMed
Bonacina 2011 {published data only}
    1. Bonacina R, Mariani U, Villa F, Villa A. Preventive strategies and clinical implications for bisphosphonate‐related osteonecrosis of the jaw: a review of 282 patients. Journal (Canadian Dental Association) 2011;77:b147. - PubMed
Bramati 2015 {published data only}
    1. Bramati A, Girelli S, Farina G, Dazzani MC, Torri V, Moretti A, et al. Prospective, mono‐institutional study of the impact of a systematic prevention program on incidence and outcome of osteonecrosis of the jaw in patients treated with bisphosphonates for bone metastases. Journal of Bone and Mineral Metabolism 2015;33(1):119‐24. - PubMed
Coviello 2012 {published data only}
    1. Coviello V, Peluso F, Dehkhargani SZ, Verdugo F, Raffaelli L, Manicone PF, et al. Platelet‐rich plasma improves wound healing in multiple myeloma bisphosphonate‐associated osteonecrosis of the jaw patients. Journal of Biological Regulators and Homeostatic Agents 2012;26(1):151‐5. - PubMed
DE Iuliis 2014 {published data only}
    1. Iuliis F, Taglieri L, Amoroso L, Vendittozzi S, Blasi L, Salerno G, et al. Prevention of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates. Anticancer Research 2014;34(5):2477‐80. - PubMed
Dimopoulos 2009 {published data only}
    1. Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Annals of Oncology 2009;20(1):117‐20. - PubMed
Lee 2014 {published data only}
    1. Lee LW, Hsiao SH, Chen LK. Clinical treatment outcomes for 40 patients with bisphosphonates‐related osteonecrosis of the jaws. Journal of the Formosan Medical Association 2014;113(3):166–72. - PubMed
Montebugnoli 2007 {published data only}
    1. Montebugnoli L, Felicetti L, Felicetti L, Gissi DB, Pizzigallo A, Pelliccioni GA, et al. Biphosphonate‐associated osteonecrosis can be controlled by nonsurgical management. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics 2007;104(4):473‐7. - PubMed
Pelaz 2014 {published data only}
    1. Pelaz A, Junquera L, Gallego L, García‐Consuegra L, Junquera S, Gómez C. Alternative treatments for oral bisphosphonate‐related osteonecrosis of the jaws: apilot study comparing fibrin rich in growth factors and teriparatide. Medicina Oral, Patologia Oral y Cirugia Bucal 2014;19(4):e320–6. - PMC - PubMed
Vescovi 2010 {published data only}
    1. Vescovi P, Manfredi M, Merigo E, Meleti M, Fornaini C, Rocca JP, et al. Surgical approach with Er:YAG laser on osteonecrosis of the jaws (ONJ) in patients under bisphosphonate therapy (BPT). Lasers in Medical Science 2010;25(1):101–13. - PubMed
Vescovi 2012 {published data only}
    1. Vescovi P, Merigo E, Meleti M, Manfredi M, Fornaini C, Nammour S. Surgical approach and laser applications in BRONJ osteoporotic and cancer patients. Journal of Osteoporosis 2012;2012:Article ID 585434, 8 pages. [DOI: 10.1155/2012/585434] - DOI - PMC - PubMed

References to ongoing studies

ACTRN12612000950864 {unpublished data only}
    1. ACTRN12612000950864. Does teriparatide reverse osteonecrosis of the jaw in patients treated with either bisphosphonates or denosumab? A randomised, controlled trial.. anzctr.org.au/Trial/Registration/TrialReview.aspx?id=362988 (first received 9 September 2012).
NCT01526915 {unpublished data only}
    1. NCT01526915. Assessment of Platelet Rich Fibrin Efficiency on Healing Delay and on Jawbone Osteochemonecrosis Provoked by Bisphosphonates (OCN/PRF). clinicaltrials.gov/ct2/show/record/NCT01526915 (first received 31 January 2012).
NCT02198001 {unpublished data only}
    1. NCT02198001. Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction (PRF). clinicaltrials.gov/ct2/show/record/NCT02198001 (first received 15 July 2014).
UMIN000009132 {unpublished data only}
    1. UMIN000009132. Study to the effect of teriparatide formulation Forteo versus Teribon on bisphosphonate‐related osteonecrosis of the jaw in osteoporosis patients. upload.umin.ac.jp/cgi‐open‐bin/ctr/ctr.cgi?function=brows&action=bro... (first received 17 October 2012).

Additional references

Anzures‐Cabrera 2010
    1. Anzures‐Cabrera J, Higgins JP. Graphical displays for meta‐analysis: an overview with suggestions for practice. Research Synthesis Methods 2010;1(1):66‐80. [DOI: 10.1002/jrsm.6; PUBMED: 26056093] - DOI - PubMed
Badros 2008
    1. Badros A, Terpos E, Katodritou E, Goloubeva O, Kastritis E, Verrou E, et al. Natural history of osteonecrosis of the jaw in patients with multiple myeloma. Journal of Clinical Oncology 2008;26(36):5904‐9. [DOI: 10.1200/JCO.2008.16.9300; PUBMED: 19018084] - DOI - PubMed
Bagan 2009
    1. Bagan J, Scully C, Sabater V, Jimenez Y. Osteonecrosis of the jaws in patients treated with intravenous bisphosphonates (BRONJ). A concise update. Oral Oncology 2009;45(7):551–4. - PubMed
Bamias 2005
    1. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. Journal of Clinical Oncology 2005;23(34):8580‐7. - PubMed
Bennett 2016
    1. Bennett MH, Feldmeier J, Hampson NB, Smee R, Milross C. Hyperbaric oxygen therapy for late radiation tissue injury. Cochrane Database of Systematic Reviews 2016, Issue 4. [DOI: 10.1002/14651858.CD005005.pub4; PUBMED: 27123955] - DOI - PMC - PubMed
Bermúdez‐Bejarano 2017
    1. Bermúdez‐Bejarano EB, Serrera‐Figallo MÁ, Gutiérrez‐Corrales A, Romero‐Ruiz MM, Castillo‐de‐Oyagüe R, Gutiérrez‐Pérez JL, et al. Prophylaxis and antibiotic therapy in management protocols of patients treated with oral and intravenous bisphosphonates. Journal of Clinical and Experimental Dentsitry 2017;9(1):e141‐9. - PMC - PubMed
Bone 2017
    1. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open‐label extension. The lancet. Diabetes & endocrinology 2017;5(7):513‐23. [DOI: 10.1016/S2213-8587(17)30138-9; PUBMED: 28546097] - DOI - PubMed
Boquete‐Castro 2016
    1. Boquete‐Castro A, Gómez‐Moreno G, Calvo‐Guirado JL, Aguilar‐Salvatierra A, Delgado‐Ruiz RA. Denosumab and osteonecrosis of the jaw. A systematic analysis of events reported in clinical trials. Clinical Oral Implants Research 2016;27(3):367‐75. [DOI: 10.1111/clr.12556; PUBMED: 25639776] - DOI - PubMed
Chamizo Carmona 2013
    1. Chamizo Carmona E, Gallego Flores A, Loza Santamaría E, Herrero Olea A, Rosario Lozano MP. Systematic literature review of bisphosphonates and osteonecrosis of the jaw in patients with osteoporosis. Reumatología clinica 2013;9(3):172‐7. [DOI: 10.1016/j.reuma.2012.05.005; PUBMED: 22784630] - DOI - PubMed
Chen 2016
    1. Chen F, Pu F. Safety of denosumab versus zoledronic acid in patients with bone metastases: a meta‐Analysis of randomized controlled trials. Oncology Research and Treatment 2016;39(7‐8):453‐9. [DOI: 10.1159/000447372; PUBMED: 27487236] - DOI - PubMed
Chestnut 2001
    1. Chestnut C, Majumdar S, Gardner J. Assessment of bone quality, quantity and turnover with multiple methodologies at multiple skeletal sites. Advances in Experimental Medicine and Biology 2001;496:95‐7. - PubMed
Coleman 2011
    1. Coleman R, Woodward E, Brown J, Cameron D, Bell R, Dodwell D, et al. Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01‐04) for women with stage II/III breast cancer. Breast Cancer Research and Treatment 2011;127(2):429‐38. [DOI: 10.1007/s10549-011-1429-y; PUBMED: 21394500] - DOI - PubMed
Comas‐Calonge 2017
    1. Comas‐Calonge A, Figueiredo R, Gay‐Escoda C. Surgical treatment vs. conservative treatment in intravenous bisphosphonate‐related osteonecrosis of the jaws. Systematic review. Journal of clinical and experimental dentistry 2017;9(2):e302‐e307. [DOI: 10.4317/jced.53504; PUBMED: 28210453] - DOI - PMC - PubMed
Copas 2009
    1. Copas J, Lozada‐Can C. The radial plot in meta‐analysis: approximations and applications. Journal of the Royal Statistical Society: Series C (Applied Statistics) 2009;58(3):329‐44. [DOI: 10.1111/j.1467-9876.2008.00650.x] - DOI
Damm 2013
    1. Damm DD, Jones DM. Bisphosphonate‐related osteonecrosis of the jaws: a potential alternative to drug holidays. General Dentistry 2013;61(5):33‐8. [PUBMED: 23928436] - PubMed
Dimopoulos 2006
    1. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, et al. Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid. Haematologica 2006;91(7):968‐71. - PubMed
Diniz‐Freitas 2016
    1. Diniz‐Freitas M, Limeres J. Prevention of medication‐related osteonecrosis of the jaws secondary to tooth extractions. A systematic review. Medicina Oral, Patologia Oral y Cirugia Bucal 2016;21(2):e250‐9. - PMC - PubMed
Dodson 2015
    1. Dodson TB. The frequency of medication‐related ssteonecrosis of the jaw and its associated risk factors. Oral and Maxillofacial Surgery Clinics of North America 2015;27(4):509‐16. [DOI: 10.1016/j.coms.2015.06.003; PUBMED: 26362367] - DOI - PubMed
Eckardt 2011
    1. Eckardt AM, Lemound D, Rana M, Gellrich N‐C. Surgical Management of Bisphosphonate‐related Osteonecrosis of the Jaw in Oncologic Patients: A Challenging Problem. Anticancer Research 2011;31:2313‐2318. - PubMed
Egger 1997
    1. Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. British Medical Journal 1997;315(7109):629‐34. - PMC - PubMed
El‐Rabbany 2017
    1. El‐Rabbany M, Sgro A, Lam DK, Shah PS, Azarpazhooh A. Effectiveness of treatments for medication‐related osteonecrosis of the jaw: a systematic review and meta‐analysis. The Journal of the American Dental Association 2017;148(8):584‐94.e2. - PubMed
Epstein 2010
    1. Epstein MS, Wicknick FW, Epstein JB, Berenson JR, Gorsky M. Management of bisphosphonate‐associated osteonecrosis: pentoxifylline and tocopherol in addition to antimicrobial therapy. An initial case series. Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontology 2010;110(5):593‐6. - PubMed
Fliefel 2015
    1. Fliefel R, Tröltzsch M, Kühnisch J, Ehrenfeld M, Otto S. Treatment strategies and outcomes of bisphosphonate‐related osteonecrosis of the jaw (BRONJ) with characterization of patients: a systematic review. International Journal of Oral Maxillofacial Surgery 2015;44(5):568–85. - PubMed
Freiberger 2009
    1. Freiberger JJ. Utility of hyperbaric oxygen in treatment of bisphosphonate‐related osteonecrosis of the jaws. Journal of Oral and Maxillofacial Surgery 2009;67(5 Suppl):96‐106. - PubMed
Gerard 2014
    1. Gerard DA, Carlson ER, Gotcher JE, et al. Early Inhibitory Effects of Zoledronic Acid in Tooth Extraction Sockets in Dogs Are Negated by Recombinant Human Bone Morphogenetic Protein. J Oral Maxillofac Surg 2014;72:61. - PubMed
GRADEPro 2014 [Computer program]
    1. GRADE Working Group, McMaster University. GRADEpro. Version 3.6. Hamilton (ON): GRADE Working Group, McMaster University, 2014.
Grbic 2010
    1. Grbic JT, Black DM, Lyles KW, Reid DM, Orwoll E, McClung M, et al. The incidence of osteonecrosis of the jaw in patients receiving 5 milligrams of zoledronic acid: data from the health outcomes and reduced incidence with zoledronic acid once yearly clinical trials program. The Journal of the American Dental Association 2010;141(11):1365‐70. [PUBMED: 21037195] - PubMed
Guarneri 2010
    1. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, et al. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast cancer research and treatment 2010;122(1):181‐8. [DOI: 10.1007/s10549-010-0866-3; PUBMED: 20361252] - DOI - PubMed
Guyatt 2002
    1. Guyatt GH, Cranney A, Griffith L. Summary of meta‐analysis of therapies for postmenopausal osteoporosis and the relationship between bone density and fractures. Endocrinology Metabolism Clinics of North America 2002;31(3):659‐79. - PubMed
Henry 2011
    1. Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double‐blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology 2011;29(9):1125‐32. [DOI: 10.1200/JCO.2010.31.3304; Pubmed: 21343556] - DOI - PubMed
Higgins 2003
    1. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ 2003;327(7414):557‐60. - PMC - PubMed
Higgins 2011
    1. Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Hinson 2015
    1. Hinson AM, Siegel ER, Stack BC Jr. Temporal correlation between bisphosphonate termination and symptom resolution in osteonecrosis of the jaw: a pooled case report analysis. Journal of Oral and Maxillofacial Surgery 2015;73(1):53‐62. [DOI: 10.1016/j.joms.2014.07.012; PUBMED: 25511956] - DOI - PubMed
Kanis 2007
    1. Kanis JA. Assessment of osteoporosis at the primary health‐care level. Technical Report. Vol. 66, Sheffield, UK: World Health Organization Collaborating Centre for Metabolic Bone Diseases,University of Sheffield, UK, 2007.
Katsarelis 2015
    1. Katsarelis H, Shah NP, Dhariwal DK, Pazianas M. Infection and medication‐related osteonecrosis of the jaw. Journal of Dental Research 2015;94(4):534‐9. - PubMed
Khan 2015
    1. Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O’Ryan F, et al. Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. Journal of Bone and Mineral Research 2015;30(1):3–23. - PubMed
Kyrgidis 2012
    1. Kyrgidis A, Triaridis S, Kontos K, Patrikidou A, Andreadis C, Constantinidis J, et al. Quality of life in breast cancer patients with bisphosphonate‐related osteonecrosis of the jaws and patients with head and neck cancer: a comparative study using the EORTC QLQ‐C30 and QLQ‐HN35 questionnaires. Anticancer Research 2012;32(8):3527‐34. [PUBMED: 22843941] - PubMed
Lee 2007
    1. Lee CY, David T, Nishime M. Use of platelet‐rich plasma in the management of oral biphosphonate‐associated osteonecrosis of the jaw: a report of 2 cases. J Oral Imlantol 2007;33:371. - PubMed
Lefebvre 2011
    1. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
Lopez‐Jornet 2010
    1. Lopez‐Jornet P, Camacho‐Alonso F, Molina‐Minano F, Gomez‐Garcia F. Bisphosphonate‐associated osteonecrosis of the jaw. Knowledge and attitudes of dentists and dental students: a preliminary study. Journal of Evaluation in Clinical Practice 2010;16(5):878‐82. - PubMed
Lopez‐Jornet 2016
    1. Lopez‐Jornet P, Perez AS, Arturo SP, Rui AM, Aurelio T. Medication‐related osteonecrosis of the jaw: Is autologous platelet concentrate application effective for prevention and treatment? A systematic review. Journal of Cranio‐maxillo‐facial Surgery 2016;44(8):1067–72. - PubMed
Lopez‐Olivo 2012
    1. Lopez‐Olivo MA, Shah NA, Pratt G, Risser JM, Symanski E, Suarez‐Almazor ME. Bisphosphonates in the treatment of patients with lung cancer and metastatic bone disease: a systematic review and meta‐analysis. Supportive Care in Cancer 2012;20(11):2985‐98. [DOI: 10.1007/s00520-012-1563-z; PUBMED: 22956190] - DOI - PMC - PubMed
Martins 2012
    1. Martins MA, Martins MD, Lascala CA, Curi MM, Migliorati CA, Tenis CA, et al. Association of laser phototherapy with PRP improves healing of bisphosphonate‐related osteonecrosis of the jaws in cancer patients: a preliminary study. Oral Oncology 2012;48(1):79‐84. - PubMed
Marx 2003
    1. Marx RE. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. Journal of Oral and Maxillofacial Surgery 2003;61(9):1115–7. [PUBMED: 12966493] - PubMed
Mauri 2009
    1. Mauri D, Valachis A, Polyzos IP, Polyzos NP, Kamposioras K, Pesce LL. Osteonecrosis of the jaw and use of bisphosphonates in adjuvant breast cancer treatment: a meta‐analysis. Breast Cancer Research and Treatment 2009;116(3):433‐9. [DOI: 10.1007/s10549-009-0432-z; PUBMED: 19521766] - DOI - PubMed
Migliorati 2003
    1. Migliorati CA. Bisphosphanates and oral cavity avascular bone necrosis. Journal of Clinical Oncology 2003;21(22):4253‐4. [DOI: 10.1200/JCO.2003.99.132; PUBMED: 14615459] - DOI - PubMed
Migliorati 2010
    1. Migliorati CA, Mattos K, Palazzolo MJ. How patients' lack of knowledge about oral bisphosphonates can interfere with medical and dental care. The Journal of the American Dental Association 2010;141(5):562‐6. - PubMed
Miksad 2011
    1. Miksad RA, Lai KC, Dodson TB, Woo SB, Treister NS, Akinyemi O, et al. Quality of life implications of bisphosphonate‐associated osteonecrosis of the jaw. The Oncologist 2011;16(1):121‐32. [DOI: 10.1634/theoncologist.2010-0183; PUBMED: 21212433] - DOI - PMC - PubMed
Morgan 2010
    1. Morgan GJ, Davies FE, Gregory WM, Cocks K, Bell SE, Szubert AJ, et al. National Cancer Research Institute Haematological Oncology Clinical Study Group. First‐line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 2010;376(9757):1989‐99. [DOI: 10.1016/S0140-6736(10)62051-X; PUBMED: 21131037] - DOI - PMC - PubMed
Nakamura 2015
    1. Nakamura M, Umetsu R, Abe J, Matsui T, Ueda N, Kato Y, et al. Analysis of the time‐to‐onset of osteonecrosis of jaw with bisphosphonate treatment using the data from a spontaneous reporting system of adverse drug events. Journal of Pharmaceutical Health Care and Sciences 2015;22(1):34. [DOI: 10.1186/s40780-015-0035-2; PUBMED: 26819745] - DOI - PMC - PubMed
Pageau 2009
    1. Pageau SC. Denosumab. mAbs 2009;1(3):210‐5. - PMC - PubMed
Patel 2015
    1. Patel V, Kelleher M, Sproat C, Kwok J, McGurk M. New cancer therapies and jaw necrosis. British Dental Journal 2015;219(5):203‐7. - PubMed
Petrucci 2007
    1. Petrucci MT, Gallucci C, Agrillo A, Mustazza MC, Foà R. Role of ozone therapy in the treatment of osteonecrosis of the jaws in multiple myeloma patients. Haematologica 2007;92(9):1289‐90. - PubMed
Qui 2014
    1. Qi WX, Tang LN, He AN, Yao Y, Shen Z. Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta‐analysis of seven randomized controlled trials. International Journal of Clinical Oncology 2014;19(2):403‐10. [DOI: 10.1007/s10147-013-0561-6; PUBMED: 23605142] - DOI - PubMed
RevMan 2014 [Computer program]
    1. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
Ripamonti 2009
    1. Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Annals of Oncology 2009;20(1):137‐45. [PUBMED: 18647964] - PubMed
Ripamonti 2011
    1. Ripamonti CI, Cislaghi E, Mariani L, Maniezzo M. Efficacy and safety of medical ozone (O(3)) delivered in oil suspension applications for the treatment of osteonecrosis of the jaw in patients with bone metastases treated with bisphosphonates: preliminary results of a phase I‐II study. Oral Oncology 2011;47(3):185‐90. - PubMed
Rollason 2016
    1. Rollason V, Laverrière A, MacDonald LCI, Walsh T, Tramèr MR, Vogt‐Ferrier NB. Interventions for treating bisphosphonate‐related osteonecrosis of the jaw (BRONJ). Cochrane Database of Systematic Reviews 2016, Issue 2. [DOI: 10.1002/14651858.CD008455.pub2] - DOI - PMC - PubMed
Ruggiero 2007
    1. Ruggiero SL. Guidelines for the diagnosis of bisphosphonate‐related osteonecrosis of the jaw (BRONJ). Clinical Cases in Mineral and Bone Metabolism 2007;4(1):37‐42. [DOI: 10.1016/j.joms.2014.04.031; PUBMED: 25234529] - DOI - PMC - PubMed
Ruggiero 2014
    1. Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and Maxillofacial Surgeons Position Paper on Medication‐Related Osteonecrosis of the Jaw—2014 Update. Journal of Oral and Maxillofacial Surgery 2014;72(10):1938‐56. [PUBMED: 25683041] - PubMed
Rupel 2014
    1. Rupel K, Ottaviani G, Gobbo M, Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical approaches in bisphosphonates‐related osteonecrosis of the jaw (BRONJ). Oral Oncology 2014;50(11):1049–57. - PubMed
Saad 2012
    1. Saad F, Brown JE, Poznak C, Ibrahim T, Stemmer SM, Stopeck AT, et al. Incidence, risk factors, and outcomes of osteonecrosis of the jaw: integrated analysis from three blinded active‐controlled phase III trials in cancer patients with bone metastases. Annals of Oncology 2012;23(5):1341‐7. [DOI: 10.1093/annonc/mdr435; PUBMED: 21986094] - DOI - PubMed
SDCEP 2017
    1. Scottish Dental Clinical Effectiveness Programme. Oral Health Management of Patients at Risk of Medication‐Related Osteonecrosis of the Jaw. Dundee, UK: SDCEP, 2017. http://www.sdcep.org.uk/published‐guidance/medication‐related‐osteonecro... (accessed 30 September 2017). - PubMed
Sigua‐Rodriguez 2014
    1. Sigua‐Rodriguez EA, Costa Ribeiro R, Brito AC, Alvarez‐Pinzon N, Albergaria‐Barbosa JR. Bisphosphonate‐related osteonecrosis of the jaw: a review of the literature. International Journal of Dentistry 2014;2014:192320. [PUBMED: 24868206] - PMC - PubMed
Silva 2016
    1. Silva LF, Curra C, Munerato MS, Deantoni CC, Matsumoto MA, Cardoso CL, et al. Surgical management of bisphosphonate‐related osteonecrosis of the jaws: literature review. Oral and Maxillofacial Surgery 2016;20(1):1–17. - PubMed
Spanou 2015
    1. Spanou A, Lyritis GP, Chronopoulos E, Tournis S. Management of bisphosphonate‐related osteonecrosis of the jaw: a literature review. Oral Diseases 2015;21(8):927–36. - PubMed
Stanton 2009
    1. Stanton DC, Balasanian E. Outcome of surgical management of bisphosphonate‐related osteonecrosis of the jaws: review of 33 surgical cases. Journal of Oral and Maxillofacial Surgery 2009;67:943‐50. - PubMed
Vescovi 2006
    1. Vescovi P, Merigo E, Meleti M, Manfredi M. Bisphosphonate‐associated osteonecrosis (BON) of the jaws: a possible treatment?. Journal of Oral and Maxillofacial Surgery 2006;64(9):1460‐2. - PubMed
Vescovi 2012a
    1. Vescovi P. Bisphosphonates and osteonecrosis: an open matter. Clinical Cases in Mineral and Bone Metabolism 2012;9(3):142‐4. [PUBMED: 23289026] - PMC - PubMed
Worthington 2015
    1. Worthington H, Clarkson J, Weldon J. Priority oral health research identification for clinical decision‐making. Evidence‐Based Dentistry 2015;16(3):69‐71. [PUBMED: 26492797] - PubMed
Xu 2013
    1. Xu SF, Adams B, Yu XC, Xu M. Denosumab and giant cell tumour of bone—a review and future management considerations. Current Oncology 2013;20(5):e442‐7. - PMC - PubMed
Zhang 2016
    1. Zhang X, Hamadeh IS, Song S, Katz J, Moreb JS, Langaee TY, et al. Osteonecrosis of the jaw in the United States Food and Drug Administration's Adverse Event Reporting System (FAERS). Journal of Bone and Mineral Research 2010;31(2):336‐40. [DOI: 10.1002/jbmr.2693; PUBMED: 26288087] - DOI - PubMed

Publication types

MeSH terms